IrelandUS drug safety inspectors have warned Genzyme Ireland Limited, a major pharmaceutical plant in Co Waterford, that it is producing 'adulterated products' due to significant violations of manufacturing standards. The FDA conducted a nine-day inspection in January 2026 and identified serious issues, particularly in the production of Thymoglobulin and Altuviiio. These problems included inadequate quality control, poor record-keeping, and insufficient investigation into manufacturing discrepancies. The FDA emphasized that Genzyme's responses to the findings were inadequate and highlighted that the company's products are now classified as adulterated under US law. While the FDA provided an opportunity for Genzyme to address these concerns, failure to do so could lead to legal actions such as seizures or injunctions. Sanofi, which owns Genzyme, stated it is taking the matter seriously and expects no immediate impact on medicine supply.
Bias read (Center): The article presents the FDA's findings and Genzyme's response neutrally, without overtly favoring either side. It includes direct quotes from the FDA and Sanofi, providing balanced perspectives on the situation.
